Prolonged Intraperitoneal Infusion of 5-Fluorouracil
Author Information
Author(s): DJ Kerr, AM Young, JP Neoptolemos, M Sherman, P Van-Geene, A Stanley, D Ferry, JW Dobbie, B Vincke, J Gilbert, D El Eini, N Dombros, G Fountzilas
Primary Institution: CRC Institute for Cancer Studies, University of Birmingham
Hypothesis
Can prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution improve treatment outcomes for patients with peritoneal carcinomatosis?
Conclusion
The study found that prolonged intraperitoneal infusion of 5-fluorouracil is tolerable and achieves significantly higher drug concentrations in the peritoneal cavity compared to systemic levels.
Supporting Evidence
- The study involved a novel carrier solution, Icodextrin 20 (7.5%), which allowed for prolonged drug delivery.
- Patients received 5-FU at doses of 200 mg/m2 and 300 mg/m2, with pharmacokinetic studies showing high peritoneal concentrations.
- Infective peritonitis was a significant complication, but redesigning the delivery system reduced its occurrence.
Takeaway
Doctors tested a new way to give cancer medicine directly into the belly, and it worked better than giving it through a vein.
Methodology
Seventeen patients with peritoneal carcinomatosis received prolonged intraperitoneal infusion of 5-fluorouracil, with a Tenckhoff catheter for drug delivery over 12 weeks.
Potential Biases
Potential bias due to the small number of patients and the observational nature of the study.
Limitations
The study had a small sample size and some patients experienced significant abdominal pain and infective peritonitis.
Participant Demographics
Patients included 7 males and 10 females, aged 21-75 years, with various prior treatments.
Want to read the original?
Access the complete publication on the publisher's website